source
- Arvinas and Pfizer license newly approved PROTAC breast cancer drug Veppanu to Rigel PharmaceuticalsArvinas and Pfizer have signed a licensing agreement that transfers ownership of their newly approved breast cancer drug, Veppanu, to San Francisco‑based Rigel Pharmaceuticals. The deal gives Arvi…
- Pfizer, Arvinas sell recently approved breast cancer drug to Rigel for $35 millionPfizer and its partner Arvinas have agreed to transfer the commercial rights of a breast cancer therapy to Rigel Pharmaceuticals. The drug had just received regulatory approval, marking a mileston…